Ipsen will be launching a new pre-filled syringe for its blockbuster rare disease drug Somatuline (lanreotide) in the EU. The new design was based on several studies, involving patients ...
Ipsen is offering $1.45 per share for Cambridge ... sales for top-selling acromegaly and neuroendocrine tumour therapy Somatuline (lanreotide). Tazverik is a first-in-class EZH2a inhibitor ...
Lanreotide 60mg/0.2mL, 90mg/0.3mL, 120mg/0.5mL; prolonged-release soln for SC inj. Lanreotide, the active component of Somatuline Depot is an octapeptide analog of natural somatostatin. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback